Skip to Main Content

Author Details

Alexandra Sch??fer
University of North Carolina at Chapel Hill
2003
85
44
PMIDPaper TitleJournal TitlePublished Year
36812267Human ACE2 expression, a major tropism determinant for SARS-CoV-2, is regulated by upstream and intragenic elements.PLoS Pathog2023
37425890Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential.bioRxiv2023
37102262Establishing a Mouse Model for Sexual Transmission and Male Reproductive Tract Persistence of Ebola Virus.J Infect Dis2023
37000623Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination.Cell Rep2023
36697369Positive-strand RNA viruses-a Keystone Symposia report.Ann N Y Acad Sci2023
35194603Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains.bioRxiv2022
35677067A Multitrait Locus Regulates Sarbecovirus Pathogenesis.bioRxiv2022
35857635SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice.Sci Transl Med2022
35862771A Multitrait Locus Regulates Sarbecovirus Pathogenesis.mBio2022
35654851Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses.Nat Immunol2022
35875685Potent and broad neutralization of SARS-CoV-2 variants of concern (VOCs) including omicron sub-lineages BA.1 and BA.2 by biparatopic human VH domains.iScience2022
36274085Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine.Nat Commun2022
36192374IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern.Nat Commun2022
35879412Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection.Nat Genet2022
35315683Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice.Sci Transl Med2022
35194605A model of persistent post SARS-CoV-2 induced lung disease for target identification and testing of therapeutic strategies.bioRxiv2022
33469219Publisher Correction: A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.Nature2021
33513210Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice.PLoS Pathog2021
33758837Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice.bioRxiv2021
33561864SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.Nature2021
34710354Stabilized coronavirus spike stem elicits a broadly protective antibody.Cell Rep2021
34547765Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy.Nature2021
34545367Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.bioRxiv2021
34619077Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.Cell2021
34270939COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge.Immunity2021
34214046Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice.Science2021
34013261Common Mechanism of SARS-CoV and SARS-CoV-2 Pathogenesis across Species.bioRxiv2021
34242577In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.Cell2021
34056628Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions.Cell Rep Med2021
33427208Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022.JCI Insight2021
33211088Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.J Exp Med2021
33442694The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates.bioRxiv2021
31621854Immune Predictors of Mortality After Ribonucleic Acid Virus Infection.J Infect Dis2020
31924756Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.Nat Commun2020
33031744A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice.Cell2020
33139569Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection.Proc Natl Acad Sci U S A2020
33398266Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions.bioRxiv2020
33024969SARS-CoV-2 D614G Variant Exhibits Enhanced Replication ex vivo and Earlier Transmission in vivo.bioRxiv2020
33160446Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.Cell2020
33184236SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo.Science2020
33232870Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate.EBioMedicine2020
33348607A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine.Vaccines (Basel)2020
32577634SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.bioRxiv2020
32941803High Potency of a Bivalent Human V<sub>H</sub> Domain in SARS-CoV-2 Animal Models.Cell2020
32887790Cell and animal models of SARS-CoV-2 pathogenesis and immunity.Dis Model Mech2020
32743571Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate.bioRxiv2020
32995791Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection.bioRxiv2020
32995782Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection <i>in vivo</i>.bioRxiv2020
32995766Acute SARS-CoV-2 Infection is Highly Cytopathic, Elicits a Robust Innate Immune Response and is Efficiently Prevented by EIDD-2801.Res Sq2020
32854108A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.Nature2020
  • 1 - 50 of 85

Recommended Authors

Sebastian Weigang
Institute of Virology, Freiburg University Medical Center, University of Freiburg
Career Start Year 2018
Number of shared co-authors 2
James Logue
Center for Pathogen Research, University of Maryland School of Medicine
Career Start Year 2017
Number of shared co-authors 10
Tianyang Mao
Yale University School of Medicine
Career Start Year 2017
Number of shared co-authors 1
Mir M Khalid
Gladstone Institutes
Career Start Year 2016
Number of shared co-authors 5
Raveen Rathnasinghe
Icahn School of Medicine at Mount Sinai New York
Career Start Year 2015
Number of shared co-authors 5
Carolina Lucas
Yale School of Medicine
Career Start Year 2014
Number of shared co-authors 1
Stuart Weston
University of Maryland School of Medicine
Career Start Year 2014
Number of shared co-authors 11
Chengjin Ye
Texas Biomedical Research Institute
Career Start Year 2013
Number of shared co-authors 3
R??my Robinot
Institut Pasteur, Universite Paris Cite, CNRS UMR 9
Career Start Year 2012
Number of shared co-authors 1
Hongjie Xia
University of Texas Medical Branch
Career Start Year 2012
Number of shared co-authors 4
Meagan E Deming
University of Maryland School of Medicine
Career Start Year 2011
Number of shared co-authors 42
Yiska Weisblum
Rockefeller University
Career Start Year 2011
Number of shared co-authors 5
Shashank Tripathi
Indian Institute of Science
Career Start Year 2011
Number of shared co-authors 7
Benjamin Israelow
Yale University School of Medicine
Career Start Year 2010
Number of shared co-authors 1
Xuping Xie
University of Texas Medical Branch
Career Start Year 2010
Number of shared co-authors 17
Jennifer Tisoncik-Go
Center for Innate Immunity and Immune Disease, University of Washington
Career Start Year 2009
Number of shared co-authors 38
Carles Mart??nez-Romero
Icahn School of Medicine at Mount Sinai
Career Start Year 2009
Number of shared co-authors 3
Judd F Hultquist
Northwestern University Feinberg School of Medicine
Career Start Year 2008
Number of shared co-authors 4
Alexander N Freiberg
University of Texas Medical Branch
Career Start Year 2008
Number of shared co-authors 7
Lisa Miorin
Icahn School of Medicine at Mount Sinai
Career Start Year 2008
Number of shared co-authors 4
Mohsan Saeed
Boston University Chobanian and Avedisian School of Medicine
Career Start Year 2007
Number of shared co-authors 2
Nicholas S Heaton
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 10
Emmie de Wit
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 2004
Number of shared co-authors 12
Benjamin R tenOever
NYU Grossman School of Medicine
Career Start Year 2001
Number of shared co-authors 9
Luis Martinez-Sobrido
Texas Biomedical Research Institute
Career Start Year 2001
Number of shared co-authors 13
Viviana Simon
Icahn School of Medicine at Mount Sinai
Career Start Year 1997
Number of shared co-authors 17
Gary P Kobinger
University of Texas Medical Branch
Career Start Year 1997
Number of shared co-authors 9
Benhur Lee
Icahn School of Medicine at Mount Sinai
Career Start Year 1995
Number of shared co-authors 17
Lucy Thorne
University College London
Career Start Year 1992
Number of shared co-authors 1
Bart L Haagmans
Erasmus Medical Center
Career Start Year 1986
Number of shared co-authors 17

Collaborators

Ralph S Baric
University of North Carolina
Co-authored papers 68
Sarah R Leist
University of North Carolina at Chapel Hill
Co-authored papers 42
Lisa E Gralinski
University of North Carolina at Chapel Hill
Co-authored papers 29
Stephanie A Montgomery
and Lineberger Comprehensive Cancer Center, University of North Carolina System
Co-authored papers 17
Ande West
University of North Carolina at Chapel Hill
Co-authored papers 13
Mark T Heise
University of North Carolina at Chapel Hill.
Co-authored papers 11
Vineet D Menachery
University of Texas Medical Branch
Co-authored papers 11
Boyd L Yount
University of North Carolina at Chapel Hill
Co-authored papers 10
Martin T Ferris
University of North Carolina.
Co-authored papers 10
Richard C Boucher
Co-authored papers 9
Fernando Pardo-Manuel de Villena
University of North Carolina
Co-authored papers 8
Kenichi Okuda
Co-authored papers 8
Mark R Denison
Vanderbilt University Medical Center
Co-authored papers 8
Darla R Miller
The University of North Carolina at Chapel Hill
Co-authored papers 7
Jason S McLellan
Co-authored papers 7
Rachel L Graham
University of North Carolina
Co-authored papers 7
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 7
Michael S Diamond
Washington University School of Medicine
Co-authored papers 6
James D Chappell
Vanderbilt University Medical Center
Co-authored papers 6
Laura J Stevens
Vanderbilt University Medical Center
Co-authored papers 6
Michael A Mooney
Knight Cancer Institute Oregon Health & Science University Portland Oregon USA.
Co-authored papers 5
Rita E Chen
Co-authored papers 5
Barton F Haynes
Co-authored papers 5
John R Mascola
Co-authored papers 5
Alan C Whitmore
University of North Carolina at Chapel Hill
Co-authored papers 5
Amy C Sims
The University of North Carolina at Chapel Hill
Co-authored papers 5
Peter Palese
Icahn School of Medicine at Mount Sinai
Co-authored papers 4
Michael G Katze
University of Washington
Co-authored papers 4
Robert H Carnahan
Vanderbilt University Medical Center
Co-authored papers 4
Rodney C Gilmore
Co-authored papers 4
Release 1.2